Business
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer,
About this update from Vir Biotechnology, Inc.
[{"type":"text","content":" SAN FRANCISCO--(BUSINESS WIRE)--\nVir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York.\n\n\nA live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.\n\n\nAbout Vir Biotechnology\n\n\nVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250825415674/en/\n\nMedia\nCorporate Communications, Vir Biotechnology\[email protected]\n\nInvestors\nRichard Lepke\nSenior Director, Investor Relations\[email protected]\n\n\nSource: Vir Biotechnology, Inc.","length":3448,"tagName":"div"}]